Table 1.
Melanoma antigen-triggered IFN-γ spot forming units in PBMC of healthy donors
| Donor no * | Tyr | MAGE-A3 | Melan-A/Mart-1 | gp100 | NY-ESO-1 | CEFpp32 |
|---|---|---|---|---|---|---|
| 2 | -/- | 4/32 | -/- | -/- | -/- | 7/11 |
| 3 | 7/22 | -/- | -/- | -/- | -/- | 197/255 |
| 4 | 10/17 | -/- | -/- | -/- | -/- | 17/22 |
| 6 | 3/22 | 5/16 | 10/13 | 5/16 | 7/13 | 80/79 |
| 7 | 51/72 | -/- | -/- | -/- | -/- | 130/170 |
| 9 | 32/42 | 2/13 | -/- | 2/13 | -/- | not tested* |
| 10 | -/- | 1/13 | -/- | -/- | -/- | not tested* |
| 11 | 17/20 | 4/14 | 5/20 | 5/13 | 3/11 | not tested* |
| 13 | -/- | 3/12 | -/- | -/- | -/- | 64/86 |
| 14 | -/- | 5/11 | -/- | -/- | -/- | 9/9 |
| 15 | -/- | 1/18 | -/- | -/- | -/- | 15/22 |
| 16 | 12/30 | 76/247 | 2/11 | -/- | -/- | 88/140 |
| 17 | 38/46 | -/- | -/- | -/- | -/- | 86/78 |
| 19 | -/- | 3/14 | -/- | -/- | -/- | 38/41 |
| 20 | -/- | 15/19 | -/- | -/- | -/- | 5/4 |
| 21 | 27/31 | -/- | -/- | -/- | -/- | 301/346 |
| 23 | -/- | -/- | 2/13 | -/- | -/- | 3/6 |
| 24 | 7/16 | 31/25 | 10/22 | 8/15 | 4/17 | 125/155 |
| 26 | 16/24 | -/- | -/- | -/- | -/- | 215/189 |
| 27 | -/- | 3/18 | 6/11 | -/- | -/- | 5/12 |
| 31 | 3/21 | 27/63 | 11/65 | 24/31 | -/- | 40/48 |
| 32 | 14/17 | -/- | -/- | -/- | -/- | 87/145 |
| 36 | 39/53 | -/- | -/- | 1/14 | -/- | 122/166 |
PBMC (250,000 per well) of the 40 healthy donors specified in Suppl. Table 1 were exposed to the specified MA or the CEFpp32
Donors no*—only those donors who respond to at least one melanoma antigen
Not tested*—CPI was used as a positive control
A Student’s t test was done comparing SFU counts for the three antigen-induced replicates with the three replicates of the corresponding medium control. The table shows results for those donors only who scored at least one positive response. The first number represents the SFU counts at 24 h, the second number, in bold, at 72 h. SFU counts that did not reach statistical significance are represented by a hyphen